406 related articles for article (PubMed ID: 8747372)
1. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
2. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
3. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
7. Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995.
J Cell Biochem Suppl; 1995; 23():1-250. PubMed ID: 8786651
[No Abstract] [Full Text] [Related]
8. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
9. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
10. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and their use in cervical cancer chemoprevention.
Vlastos AT; Schottenfeld D; Follen M
Crit Rev Oncol Hematol; 2003 Jun; 46(3):261-73. PubMed ID: 12791426
[TBL] [Abstract][Full Text] [Related]
14. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer.
Dhingra K
J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374
[TBL] [Abstract][Full Text] [Related]
15. Why phase II trials in cervical chemoprevention are negative: what have we learned?
Follen M; Vlastos AT; Meyskens FL; Atkinson EN; Schottenfeld D
Cancer Causes Control; 2002 Nov; 13(9):855-73. PubMed ID: 12462551
[TBL] [Abstract][Full Text] [Related]
16. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
17. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.
Follen M; Schottenfeld D
Cancer; 2001 May; 91(9):1758-76. PubMed ID: 11335902
[TBL] [Abstract][Full Text] [Related]
18. Intermediate biomarkers of precancer and their application in chemoprevention.
Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
[TBL] [Abstract][Full Text] [Related]
19. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
20. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]